CRISPR/$CRSP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CRISPR
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
- Ticker
- $CRSP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 393
- Headquarters
- Zug, Switzerland
- Website
- www.crisprtx.com
CRISPR Metrics
BasicAdvanced
$5.2bn
-
-$4.76
-
-
Price and volume
Market cap
$5.2bn
52-week high
$78.48
52-week low
$44.12
Average daily volume
1.6m
Financial strength
Current ratio
17.847
Quick ratio
17.791
Long term debt to equity
43.806
Total debt to equity
44.874
Profitability
EBITDA (TTM)
-513.174
Gross margin (TTM)
-3,448.33%
Net profit margin (TTM)
-3,368.72%
Operating margin (TTM)
-3,971.53%
Effective tax rate (TTM)
-0.68%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-14.20%
Return on equity (TTM)
-26.09%
Valuation
Price to revenue (TTM)
382.244
Price to book
2.99
Price to tangible book (TTM)
2.99
Price to free cash flow (TTM)
-13.695
Free cash flow yield (TTM)
-7.30%
Free cash flow per share (TTM)
-3.942
Growth
Revenue change (TTM)
-64.80%
Earnings per share change (TTM)
-12.57%
3-year revenue growth (CAGR)
-57.14%
10-year revenue growth (CAGR)
24.32%
3-year earnings per share growth (CAGR)
-3.51%
10-year earnings per share growth (CAGR)
-5.09%
What the Analysts think about CRISPR
Analyst ratings (Buy, Hold, Sell) for CRISPR stock.
CRISPR Financial Performance
Revenues and expenses
CRISPR Earnings Performance
Company profitability
CRISPR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.